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Aim: The main aim of this trial is to test the safety and efficacy of autologous stromal/
stem cells, chondrocytes or the two combined in the treatment of knee cartilage 
defects. Patients & methods: Patients with symptomatic chondral/osteochondral 
defects will be randomized to cell therapy treatment with one of three cell 
populations (1:1:1). The primary efficacy outcome is a functional knee score (Lysholm) 
at 15 months post-treatment and the primary safety outcome is the incidence of 
adverse events. Secondary objectives are to analyze repair tissues, quality of life and 
cost-utility assessments. Exploratory objectives are to identify predictors for success/
potency and dose–response relationships. Results & conclusion: This trial has been 
carefully designed so that valuable scientific and clinical information can be gathered 
throughout and in the final analysis.
First draft submitted: 10 March 2017; Accepted for publication: 19 May 2017; Published 
online: 21 June 2017
Keywords:  biomarkers • cartilage repair • cell-based therapy • cell potency • chondrocytes  
• clinical trial protocol • functional outcome measures • MSCs • reverse translational research
Cell therapy has been used clinically in 
the treatment of cartilage injury for over 
20 years [1]. There are now many variations of 
autologous chondrocyte implantation (ACI), 
but the principles for all are the same. A small 
sample of cartilage is removed from a minor 
load bearing region of a patient’s damaged 
joint; chondrocytes are isolated by mechani-
cal and enzymatic digestion and grown in 
monolayer culture in vitro. When the cell 
number has been amplified sufficiently, 
cells are implanted into the symptomatic 
defect in a second planned operation. The 
cell suspension is retained by either a patch 
of periosteum or a commercially available 
collagen membrane, sutured to the edges of 
the defect and sealed with fibrin. Our center 
has used ACI in approximately 500 proce-
dures and we and others have shown that 
it has the potential to improve functional 
outcome [2–4] and generate repair tissue that 
offers a durable surface and is well integrated 
with the surrounding cartilage [5–8]. In our 
audits of ACI, 80% of patients improve by 
15 months, and this improvement is sus-
tained for 9–16 years [3,9]. Some randomized 
controlled trials reported a significant benefit 
of ACI or matrix-applied characterized ACI 
over microfracture [10] whereas others found 
no evidence for a difference between out-
comes of these interventions in a multicenter 
randomized controlled trial [11].
A recent systematic review has suggested 
that ACI is cost-effective compared with 
microfracture across a range of scenarios [12]. 
These authors, as well as others showing the 
clear potential when comparing ACI with 
other treatments, have drawn the conclusion 
that a need exists for further large random-
ized trials with a low risk of bias and ade-
quately long follow-up to inform us of the 
best way to treat cartilage defects [13–16]. Our 
ongoing multicenter randomized controlled 
ACTIVE trial (Autologous chondrocyte 
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transplantation/implantation vs existing treatments) 
recruited 390 patients and will compare efficacy and 
cost–effectiveness data for ACI and the ‘best alterna-
tive’ treatment over a 10-year follow-up period. The 
first planned analysis of intermediate data at 5-year 
follow-up is currently taking place.
Others have favored the use of autologous bone 
marrow derived mesenchymal stromal/stem cells 
(BM-MSCs) in a similar procedure to ACI, where 
they were transplanted into cartilage defects beneath 
a periosteal flap [17–19]. One study compared the out-
come of ACI with BM-MSC treatments for cartilage 
injury in an observational study of 36 gender and 
age matched patients in each group [20]. They found 
no evidence for a difference between the groups in 
terms of functional outcome, but noted that men 
fared better than women. Drawing inferences from 
small observational studies has many disadvantages, 
and the authors recommended a randomized trial to 
compare the two types of cell therapy.
The principal outcome in all clinical studies was 
a validated knee score that measures pain and knee 
function. The Lysholm knee scale is a long-estab-
lished commonly used score. We have validated an 
improved weighting of this scale for patients with 
cartilage defects [21]. Secondary measures have mostly 
been diagnostic arthroscopy and histology of a biopsy 
of the repair tissue at 1 or 2 years. The biopsy has 
the disadvantage of only sampling a small area of 
each treated region [22,23]. In contrast, arthroscopic 
assessment can provide a recorded image of the mac-
roscopic appearance of the whole surface of the defect 
and in particular an assessment of the lateral inte-
gration, whereas MRI provides an assessment of the 
whole joint including the underlying bone [22,23].
Data described in several laboratory-based studies 
indicate that a combination of culture-expanded chon-
drocytes and BM-MSCs produce a better quality of 
cartilage matrix than BM-MSCs alone [24–26]. Fur-
ther, articular chondrocytes have been shown to ini-
tiate and drive the osteo-chondrogenic differentiation 
of BM-MSCs in in vitro coculture systems [27–29]. In 
addition, BM-MSCs have been suggested an appro-
priate choice of cell for treating larger, osteoarthritic 
defects [30] as they have both osteogenic and chondro-
genic differentiation capability [31–33] and have shown 
encouraging results in generating both tissue types in 
large animal models of osteochondral injury [34]. There 
is general agreement that BM-MSCs can contribute 
to the niche environment [35,36] and influence other 
cells’ behavior via their paracrine effect, in addition to 
having immunomodulatory effects [37]. One group is 
using chondrocytes immediately extracted from carti-
lage and combined with allogenic cultured BM-MSC 
in the clinic; this study is entitled ‘Instant Allogeneic 
MSC Product accompanying Autologous Chondron 
Transplantation’ or ‘IMPACT’. Although, the number 
of chondrocytes is necessarily low, the early reports of 
using this technique in patients are encouraging [38]. 
The IMPACT study differs from ASCOT in both the 
origin and application of the cell populations used. In 
ASCOT, both cell populations are autologous, whereas 
in the IMPACT trial the BM-MSCs are allogeneic 
and derived from young individuals. Additionally, cell 
populations in ASCOT are culture-expanded, whereas 
in the IMPACT trial, the chondrocytes were obtained 
at the time of surgery and isolated as ‘chondrons’ 
(i.e., with their capsule of matrix surrounding them).
Our approach is to build on the demonstrated 
efficacy and safety of autologous culture-expanded 
cells. The question that needs addressing is which 
type of cell, autologous BM-MSCs or chondrocytes or 
indeed, their combination, gives the most efficacious 
and safest treatment of cartilage patients, particularly 
those with more severe degenerative lesions. These are 
lesions that expose or extend into subchondral bone 
(International Cartilage Repair Society; ICRS classi-
fication III or IV) and are possibly indicative of early 
osteoarthritis [39]. We currently treat these patients 
with ACI, but the above evidence suggests that autol-
ogous BM-MSCs or a combination of autologous 
chondrocytes with autologous BM-MSCs might be 
better. To date there has been no reported random-
ized clinical trial which has investigated the combined 
use clinically of culture expanded populations or to 
have directly compared ACI and BM-MSC applica-
tions for the treatment of chondral or osteochondral 
injury. The objective of the randomized controlled 
Phase II clinical trial presented here is to test the effi-
cacy and safety of culture expanded bone marrow 
derived autologous stromal/stem cells, chondrocytes 
or a combined population of both of these for treating 
chondral or osteochondral defects in the knee.
Study design
Autologous stem cells, chondrocytes or the two 
(ASCOT) is a single-center, single-blinded, 
randomized controlled trial designed to determine 
which of three cell therapy strategies is best for treat-
ing chondral or osteochondral defects of the knee. 
The two specific research hypotheses addressed by 
the trial are: using autologous BM-MSCs to repair 
chondral or osteochondral defects in the knee gives a 
different functional outcome from using autologous 
chondrocytes. Using a combination of autologous 
BM-MSCs and autologous chondrocytes to repair 
chondral or osteochondral cartilage defects in the 
knee gives a different outcome from using either cell 
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type alone. Subjects will be randomly allocated, at a 
ratio of 1:1:1, to autologous BM-MSCs, autologous 
chondrocytes or a combination of the two. The target 
is to recruit 114 patients (38 per trial arm).
Patients & methods
Participants & outcomes
Subjects will be enrolled at a single specialist 
orthopedic hospital in the UK; the inclusion and 
exclusion criteria for the study are summarized in 
Box 1. Patients aged between 18 and 80 years of age 
with a symptomatic defect of the knee that exposes 
or extends into the subchondral bone (ICRS classifi-
cation III or IV) will be eligible to take part in this 
study. Treatment with ACI must be appropriate for 
the patient, and prior surgical treatment to the defect 
may or may not have been performed. Patients will 
be excluded from the study if they are unable to pro-
vide written informed consent to participate, do not 
adequately understand verbal explanations or written 
information given in English, have a low probability 
of compliance with rehabilitation, a defect of greater 
than 20 cm2, are shown to be positive for serology 
tests required by the cell provider, are pregnant or 
lactating. Patients will also be excluded if they show 
contraindications to autologous cell therapy, for 
example, inflammatory arthritis, current malignant 
tumor, therapy with steroids or methotrexate, opioid 
or anticoagulant medication that cannot be stopped 
prior to stage I surgery, bleeding tendency or known 
anaphylaxis to any product used in the chondrocyte 
preparation.
Interventions
Participants are assigned to one of three treatment 
arms: autologous stem cell implantation (ASI); ACI; 
or ASCI. All participants undergo an arthroscopy at 
stage I to debride the defect. Participants allocated to 
the ASI and ASCI treatment arms also undergo an 
iliac crest bone marrow biopsy; the aim of this is to 
harvest two 10 ml samples of bone marrow aspirate 
(obtained via two separate entry points) into a sterile 
tube containing heparin from which BM-MSCs are 
isolated. Participants allocated to the ACI or ASCI 
arms of the study have a hyaline cartilage biopsy taken 
during this arthroscopy; generally the central trochlea 
is used and the aim is to obtain 200 mg from which 
chondrocytes are isolated. Cell expansion takes place 
in a medicines and healthcare products Regulatory 
Agency licensed laboratory (John Charnley Labora-
tory, Cert No: UK MIA [IMP] 21276) based at the 
RJAH Orthopedic Hospital. The principal require-
ments for a satisfactory expansion are a cell count of 
1–20 million cells with a viability of at least 90% (as 
assessed by trypan blue exclusion) and no reported 
infection. One flask of cells from each culture is used 
for cell characterization studies as described below. 
The remaining cells obtained as a result of the expan-
sion process are resuspended on the day of surgery in 
the prescribed volume of excipient autologous serum 
and packaged for delivery to the operating theaters. 
Implantation of both the BM-MSC and chondro-
cyte products to repair the chondral/osteochondral 
defects is carried out during arthrotomy under ster-
ile conditions and requires both preparation of the 
defect bed and attachment of a membrane to secure 
Box 1. The inclusion and exclusion criteria for the ASCOT trial.
ASCOT inclusion criteria
•	 A symptomatic defect of the knee that exposes, or extends to or into, the subchondral bone (International Cartilage Repair 
Society; ICRS classification III or IV)
•	 The patient is aged between 18 and 80 years at the time of surgery
•	 Treatment with autologous chondrocyte implantation must be appropriate for the patient
•	 Surgical treatment (eg., debridement, abrasion, drilling, microfracture) may have been performed on the same defect at least 
6 months previously and failed to relieve symptoms
•	 The patient is able to provide written informed consent to participate in the trial
ASCOT exclusion criteria
•	 Inability to understand verbal explanations or written information (in English) or having special communication needs
•	 Likely to show contraindications to autologous cell therapy: inflammatory arthritis, previous or current malignant tumor, therapy 
with steroids or methotrexate, opioid medication that cannot be stopped prior to stage I (harvest) surgery or anticoagulant 
medication use that cannot be stopped prior to surgery, bleeding tendency or known anaphylaxis to any product used in 
chondrocyte preparation
•	 Low probability of compliance with physiotherapy or follow-up, including a major life-threatening condition, as assessed by the 
research team
•	 A defect of greater than 20 cm2 in total area
•	 The patient is shown to be positive for serology tests required by the cell provider. This includes HIV, hepatitis B and C, syphilis 
and human T-cell lymphotrophic virus I & II
•	 Pregnancy or lactation
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the implanted cells. A commercially available porcine 
collagen membrane, Chondro-Gide® (Geistlich, 
Wolhusen, Switzerland), will be used and is both 
stitched and glued (with fibrin) into place. Chondro-
Gide is the patch of choice in our center as we have 
previously shown that significantly better histological 
repair tissue was formed with regards to tissue and 
cell morphology, surface architecture and collagen 
type II production, when ACI was carried out with 
a Chondro-Gide patch rather than an autologous 
periosteal patch [8]. However, if the patient has any 
reason to avoid this (e.g., religious grounds) or if 
the membrane is not available, then an autologous 
periosteal patch will be used.
For single cell type therapies (ASI and ACI), 
one syringe containing autologous BM-MSCs or 
chondrocytes is implanted, containing between 1 
and 20 million cells, depending on the cell growth 
kinetics for each individual patient. For ASCI, two 
syringes are supplied, one containing BM-MSCs 
the other autologous chondrocytes, each containing 
between 1 and 20 million cells, again depending on 
the growth kinetics of the individual patient.
Clinical outcomes
The primary outcome measure of the ASCOT trial 
is the patient-reported knee function (Lysholm score) 
at 15 months post-treatment, taking into account the 
preoperative score as a covariate [3]. The Lysholm 
score is a validated, long-established eight-item ques-
tionnaire of knee function. The scale was originally 
designed to assess patients following knee ligament 
surgery with a special emphasis on symptoms of giv-
ing way, and this is reflected in the weighted scor-
ing system. However, we have validated an improved 
weighting of the Lysholm knee score for patients with 
cartilage defects [21] and this is the score that is used 
in this study.
The secondary outcome measures are to obtain a 
complete picture of benefit of one regenerative cell 
therapy over another, through a range of assessments, 
including histology, imaging and further measures 
of function and pain. The following parameters will 
be recorded: Incidence of adverse events; Quality 
of the repair tissue between 12 and 14 months after 
cell implantation will be assessed macroscopically 
(using both the Oswestry Arthroscopy Score and the 
ICRS arthroscopic cartilage repair assessment [40]) 
and microscopically (via needle biopsy and histologi-
cal assessment using the OsScore and the ICRS II 
histology scoring system [41]). In addition, MRI and 
computerized tomography (CT) scans will also be 
obtained and scored at baseline and between 12 and 
14 months after cell implantation. Images are ana-
lyzed using the Magnetic resonance imaging (MRI) 
Observation of Cartilage Repair Tissue Score [42] and 
Whole Organ MRI Score (WORMS [43]); Health-
related quality of life, pain, knee function, activity 
levels and general mood of the patient is assessed 
using the Veterans RAND 12-item Health Survey, 
the Intermittent and Constant Osteoarthritis Pain 
score, Knee injury and Osteoarthritis Outcome Score 
(KOOS) physical function short form (KOOS-PS), 
the modified Lysholm knee score, Human Activity 
Profile and the International Positive and Negative 
Affect Schedule Short Form scores. Each of these is 
collected at outpatient appointments on two separate 
occasions prior to ACI, and 2 months (±2 weeks), 
12 months (±4 weeks) and 15 months (± 4 weeks) 
postsurgery. Annual postal follow-ups will continue 
for up to 20 years postoperatively; Number of years 
free from further surgery; Patterns of rehabilitation 
and compliance to physiotherapy schedules are col-
lected using participant diaries throughout the reha-
bilitation program (up to 15 months postoperatively); 
Unit costs per treatment are also recorded in order to 
perform a final cost-utility analysis.
Exploratory measures aim to find correlations within 
this study which could help to predict treatment suc-
cess. For example, we aim to determine if there is a 
dose–response relationship and if so, whether there is a 
correlation between the dose (i.e., number of cells) and 
the area or volume of the defect being treated.
Cell characterization & biomarker studies
We are maximizing the potential to learn as much 
about the biology of treatment success and failure by 
studying characteristics of the cells being implanted 
and tissues collected throughout the procedure. For 
example, fat pad, synovial tissue and fluid and blood 
are being collected and analyzed for the presence of 
biomarkers which could provide additional informa-
tion on the health of the joint prior to cell implan-
tation or predict patients who will respond well to 
cell therapy [44]. In addition, we aim to gain a bet-
ter understanding of the healing response in the joint 
and how this differs between individuals by studying 
biopsy tissue from chondrocyte harvest sites, where 
the initial ‘injury’ was created under controlled con-
ditions. Finally, we are assessing the characteristics of 
both cell types for predictors of potency; such analyses 
will include cell growth kinetics and morphological 
analyses as well as RNA sequencing and immunopro-
filing by flow cytometry, using similar profile analyses 
to those we have previously published [45]. The actual 
markers analyzed for both techniques are constantly 
being updated as the study progresses to keep up to 
date with current literature and available technologies, 
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but regardless of this, all cells are assessed for their 
adherence to the International Society for Cellular 
Therapy profile for MSCs (i.e., positive for CD73, 
CD90 and CD105 and negative for CD14, CD34, 
CD45, CD19 and HLA-DR).
Sample size
A sample size of 38 patients per trial arm 
(i.e., 114 patients in total) is sufficient to test the 
two hypotheses with 80% power at p = 0.05, based 
on detecting the minimal clinically important differ-
ence in Lysholm knee scores of 13 points between the 
groups: an effect size of 0.7-times the standard devia-
tion of 18.5 in baseline Lysholm scores [3,46,47]. The 
chosen sample size allows a 10% loss to follow-up for 
various reasons in each arm, a number based on our 
multicenter trial of ACI versus alternative treatments 
(ACTIVE).
Assignment of interventions
Treatment is allocated by stratified randomization 
using the minimization method [48]. Stratification 
is based on the following known predictors of func-
tional outcome: preoperative knee score (Lysholm), 
defect location (femoral or trochlear defect vs oth-
ers), gender, age and the occurrence of previous 
marrow stimulation techniques. Randomization is 
carried out using dedicated computer software (Stra-
tOs®, Orthopaedic Institute Ltd, Oswestry, UK) and 
should not take place more than 3 months prior to 
the anticipated treatment date as delaying random-
ization will minimize pretreatment drop-out after 
randomization. Participants are blinded to the treat-
ment they have been allocated. In order to maintain 
blinding to the treatment group, those participants 
allocated to the ACI arm are given a 5-mm incision 
in the area where a bone marrow biopsy would have 
taken place if they had been allocated to either ASI or 
ASCI. Histological and imaging scoring for cartilage 
repair is performed by blinded assessors.
Statistical analysis
Our primary efficacy outcome is the Lysholm knee 
score at 15 months. This score will be used to test the 
two research hypotheses, namely: using autologous 
BM-MSCs gives a different functional outcome from 
using autologous chondrocytes; and using a combina-
tion of BM-MSCs and chondrocytes gives a different 
outcome from using either cell type alone. Statistical 
analysis of the Lysholm score will be performed as 
analysis of covariance (ANCOVA) with the treatment 
group as an independent factor, adjusting for baseline 
score, age, gender, location of defect and the occur-
rence of a previous surgical treatment. Treatment 
groups will be tested at the two-sided 5% significance 
level. The analysis will be performed as two separate 
contrast analyses, testing each of the two hypothe-
ses separately. ANCOVA is the preferred method of 
analyzing randomized trials with baseline and post-
treatment measures, with no demonstrated disadvan-
tage compared with nonparametric methods [49]. The 
results from the ANCOVA analysis will be used to 
obtain estimates of the size of the differences between 
the groups as specified by the contrasts, their 95% 
confidence intervals and their p-values. The data will 
be analyzed on an ‘intention to treat’ basis as well as 
according to actual treatment (‘per protocol’). No 
subgroup analyses are planned other than the pre-
specified subgroups defined by the stratification vari-
ables, namely preoperative functional knee score, age, 
gender, location of defect (femoral or trochlea vs oth-
ers) and previous cartilage surgery. MRI, histology, 
arthroscopy and other outcome scores will be com-
pared using one-way analysis of variance, if available 
using preoperative values as covariates. For the con-
tinuous outcome measures that are collected repeat-
edly over time (such as the Lysholm knee score), 
repeated measures analyses will be performed on the 
change from the baseline score, using standard mul-
tilevel modeling techniques [3]. Such analyses have 
the advantages of being able to combine results from 
different time-points to maximize power, and also to 
investigate the precise form of any benefit (whether, 
for example, any treatment benefit, should one exist, 
increases or decreases with time). Multilevel model-
ing also allows for suitably stratified analyses to be 
performed. Sensitivity analysis will be performed to 
determine whether any benefit of treatment is short-
lived or persists for the duration of the study. Any re-
intervention will be recorded and taken into account 
in the analysis. A health economic analysis (incorpo-
rating the Veterans RAND 12-item Health Survey) 
will estimate the cost per quality adjusted life year 
and number of years free from further surgery.
Ethical conduct & regulatory compliance
The study group received a positive ethical opinion 
from NRES Committee West Midlands – Coventry 
and Warwickshire on 29 July 2011 (11/WM/0175) 
and a Notice of Acceptance for a Clinical trial 
Authorization on 5 April 2013 (EudraCT number: 
2010–022072–31). The John Charnley Laboratory 
is a Good Manufacturing Practice approved facility 
with a manufacturers authorization for investigational 
medicinal products MIA (IMP). Interim analyses of 
major endpoints and safety data will be supplied on a 
regular basis to an independent data monitoring and 
ethics committee who will make recommendations to 
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the trial steering committee in the event of any safety 
or ethical concerns. The study will be conducted 
in accordance with the ethical principles that have 
their origins in the Declaration of Helsinki. Written 
Informed consent will be sought from all participants 
prior to any study related procedures.
Discussion
There are several published and ongoing clinical trials 
comparing cell-based therapies for the treatment of 
cartilage defects to other surgical techniques (such as 
microfracture) [10,16]. However, to-date, no randomized 
trials have been performed determining whether there 
is a difference in functional knee score post-treatment 
with chondrocytes versus BM-MSCs (the first research 
hypothesis of the present study). In addition, the third 
arm, which combines in vitro culture expanded autol-
ogous chondrocytes and BM-MSCs, represents a first-
in-man clinical intervention using a combination of 
these cell populations for the treatment of cartilage 
injury (the second research hypothesis). Furthermore, 
we have purposefully proposed a wide range of num-
ber of cells (i.e., doses) due to the fact that although a 
wide range of cell numbers are used in ACI and equiv-
alent procedures, there is no clear scientific evidence 
for the optimal dose [50]. Hence, we included a range 
covering both that examined in the reviewed literature 
(0.5 to >10 million cells/cm2 of defect area) [50] and 
the maximum range used in our center, hoping that 
the results from this trial could give an indication as 
to whether more or less cells produced a better clinical 
outcome or quality of repair tissue.
This Phase II randomized controlled trial has 
been carefully designed by a team of scientists and 
healthcare professionals in order to compare the 
safety and efficacy of the three autologous cell pop-
ulations for the treatment of cartilage injury in the 
knee. The inclusion criteria for patients were chosen 
to reflect patients who typically present in clinics in 
a secondary or tertiary referral orthopedic center. To 
this effect they may, by some definitions, be suffering 
with early osteoarthritis (which we consider as a spec-
trum of disease [39] and the age range is wider than in 
many other trials in this area [51].
Short- and long-term outcome measures will 
include Lysholm score at 15 months post-treatment, 
the occurrence of adverse events, analysis of repair 
tissues, as well as, quality of life and cost-utility 
assessments. In addition, we aim to maximize the 
opportunity for reverse translational research, so 
that we can begin to understand more fully the biol-
ogy of treatment success or failure and so that valu-
able long-term clinical information can be gathered 
throughout and in the final analysis.
Conclusion & future perspective
Results from this trial should enable us to understand 
more about the biology of cell-based treatment success 
and failure by analyzing in detail the characteristics of 
the transplanted cell populations and the joint tissues 
throughout the treatment process. It is hoped that the 
comprehensive characterization of the implanted cell 
population that will accompany the clinical trial will 
lead to a ‘signature’ of markers which can be used to 
define cell potency, a feature which is badly needed 
for the pharmaceutical label which now applies to 
Advanced Therapy Medicinal Product .
The establishment of reliable potency indicators, 
such as we hope this trial will enable, should be of 
great use to the cell therapy field and its governance. 
For example, they should facilitate the development 
of additional cell therapies, whether allogeneic or 
autologous, more rapidly by focussing on the most 
potent population.
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Executive summary
•	 There is a need for large randomized trials with a low-risk of bias and long follow-up to indicate the best treatment for cartilage 
defects.
•	 Advancements to autologous chondrocyte implantation (ACI) include using autologous bone marrow derived mesenchymal 
stromal/stem cells (BM-MSCs).
•	 The objective of this Phase II randomized controlled trial is to compare the safety and efficacy of three autologous cell 
populations for the treatment of cartilage injury in the knee.
Study design
•	 Autologous stem cells, chondrocytes, or the two is a single-center, single-blinded, randomized controlled trial designed to 
determine which of three cell therapy strategies is best for treating chondral or osteochondral defects of the knee.
•	 Hypothesis 1: using autologous BM-MSCs to repair chondral or osteochondral defects in the knee gives a different functional 
outcome from using autologous chondrocytes.
•	 Hypothesis 2: using a combination of autologous BM-MSCs and autologous chondrocytes to repair chondral or osteochondral 
cartilage defects in the knee gives a different outcome from using either cell type alone.
•	 Subjects will be randomly allocated, at a ratio of 1:1:1, to autologous BM-MSCs, autologous chondrocytes or a combination of the 
two. Recruitment target is 114 patients (38 per trial arm).
•	 Main inclusion criteria are patients aged 18–80 years old, with a symptomatic International Cartilage Repair Society (ICRS) grade 
III or IV defect, for which ACI is deemed appropriate.
•	 Main exclusion criteria are a defect of over 20cm2, positive serology tests, pregnancy/lactation, inflammatory arthritis, current 
malignancy, therapy with steroids or methotrexate, opioid or anticoagulant medication that cannot be stopped prior to stage 
surgery, bleeding tendency or known anaphylaxis to any products used.
•	 Treatment is allocated by stratified randomization using the minimization method no more than three months prior to the 
anticipated treatment date (participants are blinded to treatment allocation).
Clinical outcomes
•	 The primary outcome measure is the patient-reported knee function (Lysholm score) at 15 months post-treatment.
•	 The secondary outcome measures include histology, imaging and further measures of function and pain.
Cell characterization & biomarker studies
•	 To understand the biology of treatment success/failure, we will study the characteristics of the cells being implanted and tissues 
collected throughout the procedure (e.g., fat pad, synovial tissue/fluid and blood).
•	 Presence/absence of putative biomarkers will be analyzed to try and predict patient responses to cell therapy.
•	 Cell characteristics of the implanted population include cell growth kinetics and morphological analyses as well as RNA 
sequencing and immunoprofiling by flow cytometry.
Discussion
•	 To-date, no randomized trials have been performed determining whether there is a difference in functional knee score post-
treatment with chondrocytes versus BM-MSCs.
•	 The combination of in vitro culture expanded autologous chondrocytes and BM-MSCs, represents a ‘first-in-man’ clinical 
intervention for the treatment of cartilage injury.
•	 This cell therapy trial has been carefully designed so that an abundance of diverse clinical and scientific data is gathered 
throughout. In the final analysis, we hope to uncover biological mechanisms of failure and success so that future trials and 
treatments can be better designed in their next iteration.
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